Hong Chen - HUTCHMED DRC Executive China
| HCM Stock | USD 17.68 0.28 1.56% |
Executive
Hong Chen is Executive China of HUTCHMED DRC
| Age | 54 |
| Address | Cheung Kong Center, Hong Kong, Hong Kong |
| Phone | 852 2121 8200 |
| Web | https://www.hutch-med.com |
HUTCHMED DRC Management Efficiency
The company has Return on Asset of (0.059) % which means that on every $100 spent on assets, it lost $0.059. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0544) %, meaning that it generated no profit with money invested by stockholders. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.02. At this time, HUTCHMED DRC's Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Total Current Assets is likely to grow to about 1.2 B, while Non Currrent Assets Other are likely to drop about 11 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Iain Brown | Alkermes Plc | 55 | |
| Peter Norman | Alkermes Plc | N/A | |
| Samuel Parisi | Alkermes Plc | 49 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Ronald Silver | Ironwood Pharmaceuticals | 41 | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Jose Vieira | Procaps Group SA | 58 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Lauren Riker | Pacira BioSciences, | 45 | |
| Craig MD | Alkermes Plc | 56 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Andrew Davis | Ironwood Pharmaceuticals | 37 | |
| Esq III | Pacira BioSciences, | 50 | |
| Karen Esq | Intracellular Th | 62 | |
| Christopher Young | Pacira BioSciences, | 52 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| DO Ellis | Pacira BioSciences, | 53 | |
Management Performance
| Return On Equity | -0.0544 | ||||
| Return On Asset | -0.059 |
HUTCHMED DRC Leadership Team
Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kin MBA, Senior Communications | ||
| CA BEc, CFO Director | ||
| CS CGP, Company Director | ||
| Yiling Cui, Executive Operations | ||
| Charles Nixon, Group Counsel | ||
| Qingmei Wang, Senior Alliances | ||
| BSE CS, Company Director | ||
| Selina Zhang, Senior Resources | ||
| Karen Atkin, Executive COO | ||
| Zhenping MBA, Executive Manufacturing | ||
| David Ng, Head Strategies | ||
| Hong Chen, Executive China | ||
| ACGI BSc, Ex Chairman | ||
| Weiguo BSc, Chief CEO |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0544 | ||||
| Return On Asset | -0.059 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 2.36 B | ||||
| Shares Outstanding | 170.93 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 4.28 % | ||||
| Number Of Shares Shorted | 573.62 K | ||||
| Price To Earning | 335.94 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.84) | Earnings Share (0.25) | Revenue Per Share 3.575 | Quarterly Revenue Growth (0.43) | Return On Assets (0.06) |
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.